Incisive Technologies Pty

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Incisive Technologies Pty sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting upper half by trial count

Incisive Technologies Pty: 1 sponsored US clinical trial, none currently recruiting.

Incisive Technologies Pty sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. The most-studied condition in this pipeline is Dental Caries, with 1 trials.

Mid-pack sponsor footprint

Incisive Technologies Pty is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

1 total, page 1 of 1

ACTIVE NOT RECRUITING NA

In-situ Clinical Trial Assessing Ability to Detect and Monitor Active Caries and Their Remineralization

NCT07100626

Therapeutic Areas

Dental Caries 1

How the Incisive Technologies Pty archive is shaped

1 indexed studies, none listed as recruiting (0% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Dental Caries (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Incisive Technologies Pty: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Incisive Technologies Pty sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Incisive Technologies Pty1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Incisive Technologies Pty sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Incisive Technologies Pty sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Incisive Technologies Pty page

1 registered trials is a research-attention snapshot, not an endorsement of Incisive Technologies Pty or any single study.

  • None of Incisive Technologies Pty's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dental Caries is the condition Incisive Technologies Pty studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dental Caries trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Incisive Technologies Pty pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.